Daniel Morgensztern
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Purpose: Recent advances have seen the development of targeted therapeutics against the receptor tyrosine kinase (RTK)/RAS/MAPK pathway, which, when aberrantly activated, drives the malignant transformation of many cancer indications. However, the efficacy of inhibitors targeting single molecules is dampened by pathway feedback activation and acquired drug resistance. We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway–targeted combination therapies. Furthermore, SHP2 plays a vital role in PD-1–mediated immunosuppression. The rational combination of JAB-3312 with PD-1 blocking therapies is also explored. Experimental Design: Biochemical and cellular assays were applied to evaluate the potency of JAB-3312 in SHP2 inhibition. Tumor cell lines and cell line– and patient-derived xenografts were used to test different combinations of JAB-3312 with KRAS G12C , MEK, EGFR, and PD-1 inhibitors. Results: JAB-3312 produced potent in vitro inhibition of SHP2 activity and downstream ERK phosphorylation, with IC 50 values of 1.44 nmol/L and 0.68 to 4.84 nmol/L, respectively. When used in combination, JAB-3312 significantly increased the antitumor activity of the KRAS G12C inhibitor glecirasib in naïve and resistant models. The combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. The JAB-3312–osimertinib combination exhibited great efficacy in osimertinib-resistant non–small cell lung cancer models. Additionally, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting an antitumor microenvironment. Representative cases of patients who responded to the combination therapies from two ongoing clinical trials (NCT05288205 and NCT04720976) were reported. Conclusions: JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.
Year:
2025
Supplementary Figure S5. JAB-3312 in combination with MEK inhibitor synergistically inhibited cancer cell growth in vitro and did not affect the weight gain of mice. A-B. Proliferation inhibition of SW620 human colon cancer cells by JAB-3312, MEKi, or their combination. C-E. The body weight change of SW620 (C), CR1554 (D), and CR3262 (E) xenograft models during the treatment of JAB-3312, MEKi, and the combination. Mean ± SEM was shown.
Year:
2025
Supplementary Figure S9. The anti-tumor activity of JAB-3312 was abrogated by CD8+ T cell depletion. A-B. Tumor growth change (A) and body weight change (B) of MC38 syngeneic model during the treatment. Mean ± SEM was shown.
Year:
2025
Supplementary Figure S6. The combination of JAB-3312 and EGFR inhibitor osimertinib synergistically inhibited cancer cell growth in vitro and did not affect the weight gain of mice. A-B. Proliferation inhibition of NCI-H1975 (A) and NCI-H1975-C797S (B) human lung cancer cells by JAB-3312, osimertinib, or their combination. C-D. The body weight change of NCI-H1975 (C) and LUN#2355-214 (D) xenograft models during the treatment of JAB-3312, osimertinib, and the two-drug combination. Mean ± SEM was shown.
Year:
2025
Supplementary Figure S2. The combination of JAB-3312 and glecirasib can enhance the inhibitory effect on the growth of KRASG12C mutant tumors in vitro and in vivo. A. Proliferation inhibition of SW837 human colon cancer cells by JAB-3312, glecirasib, or their combination. B-E. The tumor volume change of SW837 (B), MIA PaCa-2 (C), CR6243 (D), and CR6256 (E) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean tumor volumes ± SEM were shown.
Year:
2025
Supplementary Figure S3. Body weight change of KRASG12C mutant tumors. A-E. Body weight change of SW837 (A), MIA PaCa-2 (B), CR6243 (C), CR6256 (D), and LU6405 (E) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean ± SEM was shown.
Year:
2025
Supplementary Figure S4. Body weight change of KRASG12C inhibitor resistance models. A-B. Body weight change of NCI-H1373 GlecirasibR (A) and NCI-H1373 SotorasibR (B) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean ± SEM was shown.
Year:
2025
Supplementary Figure S10. CT images of representative clinical cases over the course of treatment. A. Images of the target legions (nodules in the lower lobe of the right lung and the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. B. Images of the target legion (nodule in the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. C. Images of the target legion (nodule in the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. D. Images of the target legion (intra-abdominal nodule) over time in a patient with KRAS G12V mutant ovarian serous carcinoma who received JAB-3312 and binimetinib combination therapy. E. Images of the target legion (left abdominal wall nodule) over time in a patient with ESCC who received JAB-3312 and pembrolizumab combination therapy.
Year:
2025
PURPOSE The National Comprehensive Cancer Network (NCCN) guidelines recommend comprehensive genomic profiling (CGP) for identifying advanced non–small cell lung cancer (NSCLC) patients eligible for targeted treatment, with frequent updates to incorporate new variant-targeted therapies. CGP panels can identify multiple actionable biomarkers from a single sample to match patients to targeted therapies. We assessed the adherence rate of NCCN recommendations to variant-specific matched therapy, the impact of timing of guideline updates on adherence rates, and time from sequencing to new targeted therapy adoption. METHODS We conducted a retrospective cohort study of stage IV NSCLC patients, with Tempus xT tissue-based sequencing. Adherence to NCCN-recommended therapy was defined as the proportion of patients who initiated guideline-directed targeted therapy when the presence of an actionable variant was identified. RESULTS Among the 1,407 evaluable patients, 233 patients had a NCCN-recommended targetable variant. The treatment adherence rate was 86.3% (N = 201) with median time from sequencing to targeted therapy initiation of 23 days. A subset of adherent patients (13.4%, n = 27) had targetable variants identified prior to guideline recommendation for testing, but received matched targeted therapy within a median of 96 days of new guidelines recommendations. The variant-specific adherence rate was correlated with the timing of guideline recommendation ( P = .02, Wald test), with lower adherence rates for variant-matched therapies recently included into guidelines. CONCLUSION In a large, real-world cohort of advanced NSCLC patients tested with CGP, the treatment adherence rate to matched NCCN-recommended targeted therapy was high. This study highlights the importance of CGP testing in identifying variants to provide timely matched targeted therapy in a rapidly evolving biomarker and therapeutic landscape.
Year:
2025
Purpose: Recent advances have seen the development of targeted therapeutics against the receptor tyrosine kinase (RTK)/RAS/MAPK pathway, which, when aberrantly activated, drives the malignant transformation of many cancer indications. However, the efficacy of inhibitors targeting single molecules is dampened by pathway feedback activation and acquired drug resistance. We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway–targeted combination therapies. Furthermore, SHP2 plays a vital role in PD-1–mediated immunosuppression. The rational combination of JAB-3312 with PD-1 blocking therapies is also explored. Experimental Design: Biochemical and cellular assays were applied to evaluate the potency of JAB-3312 in SHP2 inhibition. Tumor cell lines and cell line– and patient-derived xenografts were used to test different combinations of JAB-3312 with KRASG12C, MEK, EGFR, and PD-1 inhibitors. Results: JAB-3312 produced potent in vitro inhibition of SHP2 activity and downstream ERK phosphorylation, with IC50 values of 1.44 nmol/L and 0.68 to 4.84 nmol/L, respectively. When used in combination, JAB-3312 significantly increased the antitumor activity of the KRASG12C inhibitor glecirasib in naïve and resistant models. The combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. The JAB-3312–osimertinib combination exhibited great efficacy in osimertinib-resistant non–small cell lung cancer models. Additionally, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting an antitumor microenvironment. Representative cases of patients who responded to the combination therapies from two ongoing clinical trials (NCT05288205 and NCT04720976) were reported. Conclusions: JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (10)
David Carbone
Ohio State University Medical Center
Tianhong Li
Professor of Clinical Medicine
University of California Davis School of Medicine
Wade T. Iams
-
Giordano Fabricio Cittolin Santos
Assistant Professor
Washington University in St. Louis
Aparna Hegde
The University of Alabama
Muhammad Furqan
Professor
University of Oklahoma Health Sciences Center
Susanne Arnold
University of Kentucky
Toshiyuki Kozuki
Kochi Medical School, Kochi University
Luis E. Raez
-
Afshin Dowlati
-
Make your next move.
Prepare your application
Review drafts before you send them.